Peginterferon beta-1a

Peginterferon beta-1a
Clinical data
Trade names	Plegridy, Plegridy Pen
AHFS/Drugs.com	Monograph
MedlinePlus	a614059
License data	EU EMA: by INN; US DailyMed: Peginterferon_beta-1a;
Pregnancy; category	AU: D; ;
Routes of; administration	Subcutaneous injection
Drug class	Antineoplastic agent
ATC code	L03AB13 (WHO) ;
Legal status
Legal status	US: ℞-only ; EU: Rx-only ; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl);
CAS Number	1211327-92-2;
DrugBank	DB09122;
UNII	I8309403R0;
KEGG	D10483;
Chemical and physical data
Formula	C913H1417N246O256PS7 [C2H4O]n
Molar mass	44 000 g·mol−1

Peginterferon beta-1a', sold under the brand name Plegridy, is medication used to treat multiple sclerosis.

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.^[3]^[2]

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.^[4]^[3]

Medical uses[]

In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.^[2]

In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.^[3]

References[]

^ ^a ^b "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Retrieved 25 June 2020.
^ ^a ^b ^c "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020.
^ ^a ^b ^c ^d "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020.

External links[]

"Peginterferon beta-1a". Drug Information Portal. U.S. National Library of Medicine.
Plegridy at the US National Library of Medicine Medical Subject Headings (MeSH)

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

[Drugs.com_pregnancy-1] "Peginterferon beta-1a (Plegridy) Use During Pregnancy". Drugs.com. 22 July 2019. Retrieved 25 June 2020.

[Plegridy_FDA_label-2] "Plegridy- peginterferon beta-1a kit Plegridy Pen- peginterferon beta-1a kit Plegridy- peginterferon beta-1a injection, solution". DailyMed. 30 March 2020. Retrieved 25 June 2020.

[Plegridy_EPAR-3] "Plegridy EPAR". European Medicines Agency (EMA). Retrieved 24 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[4] "Drug Approval Package: Plegridy (peginterferon beta-1a) prefilled syringe and Plegridy Pen (peginterferon beta-1a) prefilled pen NDA #125499". U.S. Food and Drug Administration (FDA). 17 September 2014. Retrieved 25 June 2020.

[1]

[2]

[3]

[4]